Oric Pharmaceuticals, Inc.

ORICSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1796280

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Operating Expenses	$142.9M	$110.8M	$91.8M	$78.9M	$28.6M
Operating Income (Loss)	-$142.9M	-$110.8M	-$91.8M	-$78.9M	-$28.6M
Nonoperating Income (Expense)	$15.0M	$10.1M	$2.6M	$156.0K	$1.7M
Income Tax Expense (Benefit)	$0.00	$0.00	$0.00	$0.00	$0.00
Net Income (Loss) Attributable to Parent	-$127.8M	-$100.7M	-$89.1M	-$78.7M	-$26.9M
Earnings Per Share, Basic	-$1.83	-$1.96	-$2.25	-$2.07	—
Earnings Per Share, Diluted	-$1.83	-$1.96	-$2.25	-$2.07	—

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$274.1M	$252.0M	$247.2M	$298.6M	$299.0M
Assets, Current	$262.3M	$212.6M	$210.5M	$240.5M	$296.7M
Cash and Cash Equivalents, at Carrying Value	$59.4M	$23.4M	$66.8M	$226.0M	$89.2M
Liabilities	$31.0M	$27.9M	$24.8M	$25.7M	$9.2M
Liabilities, Current	$24.8M	$20.5M	$15.4M	$15.2M	$9.0M
Long-term Debt	—	—	—	—	$10.5M
Accounts Payable, Current	$1.5M	$944.0K	$1.3M	$1.9M	$757.0K

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$112.7M	-$85.7M	-$75.1M	-$59.5M	-$23.5M
Net Cash Provided by (Used in) Investing Activities	$22.1M	-$43.4M	-$109.2M	$158.4M	-$768.0K
Net Cash Provided by (Used in) Financing Activities	$126.5M	$85.7M	$25.2M	$49.1M	$70.8M
Payments to Acquire Property, Plant, and Equipment	$1.2M	$849.0K	$2.1M	$939.0K	$768.0K

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)